BEVERLY HILLS, Calif., June 16,
2021 /PRNewswire/ -- GT Biopharma, Inc. ("GT
Biopharma" or the "Company") (NASDAQ: GTBP), a clinical stage
immuno-oncology company focused on developing innovative
therapeutics based on the Company's proprietary natural killer (NK)
cell engager (TriKE™) protein biologic technology platform, today
announced that it will provide a corporate update at the upcoming
Raymond James Human Health Innovation Conference on Tuesday, June 22, 2021 at 11:20 AM ET.
A live webcast of the event will be available by visiting
"Presentations" page in the Investors section of GT Biopharma's
website at www.gtbiopharma.com/news-media/presentations. A replay
of the webcast will be archived for 30 days following the
presentation.
About GT Biopharma, Inc.
GT Biopharma, Inc. is a
clinical stage biopharmaceutical company focused on the development
and commercialization of immuno-oncology therapeutic products based
on our proprietary TriKE™ NK cell engager platform. Our
TriKE™ platform is designed to harness and enhance the cancer
killing abilities of a patient's immune system's natural killer
cells (NK cells). GT Biopharma has an exclusive worldwide
license agreement with the University of
Minnesota to further develop and commercialize therapies
using TriKE™ technology. For more information, please visit
gtbiopharma.com.
Investor
Contact:
|
Investor and Media
Relations Contact:
|
Brendan
Payne
|
David
Castaneda
|
Client
Lead
|
David@gtbiopharma.com
|
Stern Investor
Relations, Inc.
|
414-351-9758
|
brendan.payne@sternir.com
|
|
212-362-1200
|
|
View original
content:http://www.prnewswire.com/news-releases/gt-biopharma-to-present-at-raymond-james-human-health-innovation-conference-301313508.html
SOURCE GT Biopharma, Inc.